3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Status
Completed
21
Recruiting
6
Unknown
5
Withdrawn
4
Active not recruiting
4
Terminated
2
Not yet recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
5
Other hematologic neoplasm
4
Gastrointestinal
4
Thoracic
3
Lymphoid
3
Other
2
Genitourinary
2
Other solid neoplasm
1
Myeloid
1
Gynecologic
1
Conditions
Urinary Bladder Neoplasms
1
Prostatic Neoplasms
1
Peripheral Nervous System Diseases
1
Motor Activity
1
Interventions
Gemcitabine
13
Radiotherapy
12
Androgen Antagonists
12
Specimen Handling
11
Magnetic Resonance Spectroscopy
10
pembrolizumab
9
Nivolumab
8
toripalimab
7
darolutamide
7
Drug Therapy
7
Radiosurgery
6
Docetaxel
6
Cystectomy
6
enzalutamide
5
apalutamide
5
Mitomycin
5
Cisplatin
5
Axitinib
5
Abiraterone Acetate
5
disitamab vedotin
4
cabozantinib
4
abiraterone
4
Pluvicto
4
Cyclophosphamide
4
tislelizumab
3
lenvatinib
3
fludarabine
3
cemiplimab
3
Sunitinib
3
Standard of Care
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Exercise
×
Genitourinary
×
Clear all
NCT07548476
2026-05-04
ACE
Dana-Farber Cancer Institute
Phase NA
Not yet recruiting
50 enrolled
NCT07518888
2026-04-09
ESCAPE
University of Miami
Phase NA
Not yet recruiting
49 enrolled